Biotechnology
Commented by Fabian Lorenz on November 17th, 2022 | 10:40 CET
Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?
Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.
Read
Commented by Armin Schulz on November 16th, 2022 | 13:30 CET
BioNTech, Meta Materials, and Amazon - Industry leaders belong in the portfolio
In 2021, the stock market world was still in order - it had been going nowhere but up for years. That was the peak of the stock hype, and many top dogs in their industries were very expensive from a fundamental point of view. That has changed significantly this year. Due to the Ukraine conflict, rising interest rates and ever-higher inflation, many industry leaders had to make significant losses. Even a drop of 50% was not uncommon. Yet the long-term outlook is good. Now that the stock market is slowly regaining momentum, it is worth taking a look at three companies that are leaders in their field.
Read
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read
Commented by Fabian Lorenz on November 9th, 2022 | 13:31 CET
BioNTech, Porsche and Pathfinder Ventures - Looking good
BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.
Read
Commented by Armin Schulz on November 7th, 2022 | 10:31 CET
BioNTech, Cardiol Therapeutics, Bayer - Strong growth in the pharmaceutical industry over the coming years
Demographic change is bringing new customers to pharmaceutical and biotech companies. Worldwide, the population is getting older, and with it, the number of patients with dementia, cancer and heart disease. Experts estimate that the population over 65 will increase steadily until 2050. The 'pill gap' will start to have a real impact from 2030, and then the proportion of the aging population will rise again in proportion. Accordingly, all healthcare companies will see growth as the number of customers grows. So today, we look at three companies committed to better patient health.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Armin Schulz on November 2nd, 2022 | 14:10 CET
BioNTech, XPhyto Therapeutics, MorphoSys - Biotech stocks facing a renaissance?
While the Corona pandemic plunged many companies into crisis, the biotech sector was the big winner. The fastest vaccine developers raked in record profits and are still profiting from vaccine orders today. Meanwhile, the Corona Crisis is no longer the focus of attention in many parts of the world. This is one of the reasons why the NASDAQ Biotech Index suffered significant losses until the end of September. In some cases, the shares of biotechnology companies were trading below their cash levels. Since October, things have been on the upswing. Reason enough to take a look at three interesting biotech companies.
Read
Commented by André Will-Laudien on October 31st, 2022 | 13:31 CET
Top biotech shares - Now on the up: Bayer, Cardiol Therapeutics, BioNTech, Pfizer
The fight against the two "common diseases" of cancer and cardiovascular disease continues with a major infusion of resources. In early 2022, President Biden announced a new edition of the "Cancer Moonshot" and named new goals: To halve the cancer death rate within 25 years and significantly improve the lives of people with cancer. The most common cause of death in Germany, on the other hand, is cardiovascular disease. With around 338,000 deaths in 2020, it accounted for more than a third of the 985,500 deaths. The second most common cause of death was primarily cancer, followed by diseases of the respiratory system. The biotech industry thus continues to face major challenges. Who is well positioned?
Read
Commented by Fabian Lorenz on October 28th, 2022 | 12:54 CEST
BioNTech, Nel ASA and Desert Gold - Ripe for uptrend?
The profit warning at ITM Power sent shockwaves throughout the hydrogen sector. Does this mean that the friendly development of the Nel share of the past few days has already ended? Analysts see little potential, at least at present, but are optimistic for the long term. Goldman Sachs is also optimistic about the gold price. At least the chances for a rise to over USD 2,000 are better than for a renewed decline. Producers like Barrick Gold should profit from this, and explorers like Desert Gold even disproportionately. At BioNTech, there is currently no impetus for an upward trend, and analysts' price targets diverge considerably. However, rumors from the US are encouraging.
Read
Commented by Stefan Feulner on October 26th, 2022 | 11:28 CEST
Biogen, Cardiol Therapeutics, Evotec - Brilliant results
The reporting season for the third quarter is in full swing and is creating a thoroughly positive mood. For example, the software group SAP posted surprisingly strong growth in its cloud business in the third quarter, and its operating result was better than forecast. Positive signals are also coming from the biotech sector, which has been badly battered in recent months. After the horrendous share price losses, this sector, in particular, offers attractive long-term entry levels.
Read